Alemtuzumab + Rituximab Consolidation in CLL: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Alemtuzumab + Rituximab Consolidation in CLL (NCT00771602), a randomized phase 2 study. The primary outcome is Number of Patients With Molecular Remissions at 52 Weeks.

2. Clinical Question

The study’s stated purpose was to examine how well the treatments might control CLL left after chemotherapy and to study their safety. The primary endpoint focuses on molecular remission, rather than a symptom measure or a time-to-event outcome. Progression-free survival and 52 Week Toxicity Rate are listed as secondary outcomes.

The registry identifies a randomized, parallel-group, unmasked trial, but the posted record does not give an analyzable comparison of the treatment groups. It reports enrollment of 1 and says the study was terminated because of slow accrual. Its primary-outcome note says no analysis was available because the participant was ineligible for evaluation. Consequently, the recorded research question is clear, but the posted results do not answer whether the treatment groups differed on molecular remission.

3. Trial Design

The registry describes a randomized, parallel-group PHASE2 trial sponsored by M.D. Anderson Cancer Center. Masking is listed as none. The study compared rituximab alone, alemtuzumab alone, and the combination as consolidation therapy for patients with CLL and residual disease following prior chemo(immuno)therapy. The record lists enrollment of 1.

The rituximab-alone group is described as receiving 375 mg/m^2 IV rituximab. The alemtuzumab-alone group is described as receiving 30 mg SQ alemtuzumab. The combination group is described as receiving 375 mg/m^2 rituximab plus 30 mg SQ alemtuzumab. Dosing schedules, treatment duration, and other implementation details are not reported in the registry record.

The listed study start is 2008-08, and primary completion is listed as 2010-12. The current status is TERMINATED. The primary-outcome note attributes termination to slow accrual and states that no analysis was available because the participant was ineligible for evaluation. These entries describe the registry record; they do not establish how treatment assignment was implemented or how many people were screened, approached, or excluded.

Progression-free survival and 52 Week Toxicity Rate are listed as secondary outcomes. The primary endpoint is the number of patients with molecular remissions at 52 weeks. Although the study is labeled randomized, the registry record does not report the sequence-generation method, allocation concealment, or the procedures used to maintain treatment assignment. It also does not report a completed comparison of the groups. Thus, the design labels describe the intended structure, while the limited enrollment and lack of an evaluable primary analysis prevent assessment of comparative outcomes.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Study was closed early as result of low accrual.

Overall Study

Analysis population for the primary outcome, as defined in the registry: No analysis available participant ineligible for evaluation; study terminated due to slow accrual.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Patients With Molecular Remissions at 52 Weeks, measured over 52 weeks.

The primary endpoint is the number of patients with molecular remissions at 52 weeks. The registry defines molecular remission as minimal residual disease (MRD) flow cytometry-negative status after monoclonal antibody consolidation therapy. In its description, this means resolution of all detectable disease below the limits of sensitivity of the MRD flow cytometry assay.

As a general statistical concept, an assay-based endpoint can capture disease burden at a level not necessarily represented by a broader clinical outcome. MRD negativity is therefore used as a measure of whether disease remained detectable by the specified assay at the stated assessment time. The result depends on the assay’s sensitivity: a negative reading means disease was not detected within that assay’s limits, not that every possible trace of disease has been excluded.

The registry’s primary-outcome note says no analysis was available because the participant was ineligible for evaluation. Therefore, the record does not report an observed molecular-remission count, a rate, or a comparison between groups. The endpoint’s definition is available, but the posted results do not show how any group performed at 52 weeks. The reasons for ineligibility beyond the registry’s wording, the assessment procedures, and any rules for handling an unavailable assessment are not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry identifies the study as randomized, parallel-group, and unmasked. In general, randomization assigns participants to treatment groups by chance, with the aim of reducing systematic differences between groups. A parallel-group design means participants are assigned to a group and assessed under that group’s treatment, rather than switching between treatments as part of a crossover design. An unmasked study does not conceal assigned treatment from participants or investigators. These design labels describe the intended comparison; they do not by themselves demonstrate that an informative comparison was completed.

Here, the treatment groups are rituximab alone, alemtuzumab alone, and the combination. The record reports enrollment of 1, states that the participant was ineligible for primary-outcome evaluation, and lists no analyses. This means there is no reported estimate comparing molecular remission across the groups. Randomization can support causal interpretation when outcome data and an appropriate analysis are available, but it cannot supply missing outcomes or overcome the absence of an analyzable comparison.

For a binary endpoint such as MRD flow cytometry-negative status, a completed analysis might report the number meeting the endpoint and the number assessed in each group. A treatment comparison could then be expressed with an effect estimate and an interval describing uncertainty. These are general statistical concepts, not results reported for this study. The registry provides neither the primary endpoint counts nor an effect estimate or confidence interval. A p-value would address compatibility between data and a specified null hypothesis under an analysis model; no such p-value is reported.

A confidence interval is a range of values generated by a statistical procedure to convey uncertainty around an estimate. A narrow interval generally indicates greater precision than a wide interval, given the model and data. In this record, there is no primary treatment-effect estimate around which to interpret an interval. The absence of an interval is not evidence that an effect is exactly zero, and the absence of a p-value is not evidence that groups are equivalent. The registry does not report a noninferiority or equivalence analysis.

The record lists progression-free survival as a secondary outcome. In general, time-to-event analyses account for both the time until an event and the fact that some participants may not have had an event by the end of observation. Such analyses require event and follow-up information and defined analysis methods. The registry does not report a progression-free survival estimate, event counts, follow-up distribution, censoring rules, or a model. No time-to-event conclusion can be drawn from the outcome name alone.

The registry also lists 52 Week Toxicity Rate. In general, rates require a defined event, an observation window, and a denominator that represents the participants assessed or at risk under the analysis definition. The posted safety entries give counts for at-risk and affected participants, but do not provide a completed toxicity-rate comparison or define how the listed secondary outcome was analyzed. Counts should not be converted into a comparative rate when the analysis population and group denominators are not reported.

Some planning illustrations use sample-size assumptions rather than observed trial outcomes. The stated assumptions specify a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. The effect to detect is described as a stated fraction of the observed effect. For time-to-event outcomes, the planning convention is a total number of events; for other outcomes, it is participants per arm. In general, these are hypothetical planning quantities under chosen assumptions, not observed participants, events, or evidence that a trial had adequate power. They must not be described as observed power.

The registry does not report the trial’s own sample-size justification or statistical analysis plan. It does not report whether any interim analyses were planned or conducted, which covariates might have been used, or how the primary comparison was intended to be estimated. Such details matter because they define the analysis, its assumptions, and how uncertainty is quantified. Their absence means that the planned statistical approach cannot be reconstructed from the registry record.

Over-dispersion is a general concern when count data vary more than a chosen model expects; accounting for it can change estimated uncertainty. That concept does not identify an appropriate model for this trial, because the registry record does not report an analyzed count outcome or model specification. More broadly, statistical methods should match the endpoint and the available data. The posted record documents the endpoint definition and design labels, but does not provide enough outcome or analysis information to evaluate model fit, precision, or treatment contrasts.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary endpoint and the secondary outcomes progression-free survival and 52 Week Toxicity Rate. It does not report how multiple outcomes or treatment comparisons were handled statistically. In general, when several hypotheses are tested, the chance of at least one apparently unusual result can increase unless the analysis plan accounts for multiplicity. The registry record does not describe a multiplicity adjustment, a hierarchy of hypotheses, or a prespecified testing sequence. Because no analyses are listed, there are no posted p-values to assess for multiplicity in any case.

Missing-outcome handling is also not reported. The primary-outcome note says the participant was ineligible for evaluation, but it does not explain the reason for ineligibility or state how that participant was handled in the analysis population. The record does not report imputation methods, a missing-data sensitivity analysis, or rules for incomplete follow-up. These details should not be inferred from the endpoint definition.

The record does not specify whether the intended analysis population was based on assignment, treatment received, or eligibility for evaluation. In general, an intention-to-treat analysis retains participants in their assigned groups, while other analysis populations may apply different eligibility or treatment-exposure rules. The registry does not say which approach was planned or used, and its primary result was not available for analysis. It is therefore not possible to determine whether the posted safety entries or any other outcome counts represent the same analysis population.

The sample-size illustrations are planning exercises under stated assumptions, not a replacement for a reported analysis plan. The trial’s own sample-size justification, interim-analysis plan, missing-data strategy, and analysis-population definitions are not reported in the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent non-serious adverse event terms

The registry’s serious adverse event entries list rituximab with 1 at risk and 0 affected. Alemtuzumab and rituximab plus alemtuzumab each have 0 at risk and 0 affected. The serious adverse event terms list is empty. Deaths are not reported in the registry record.

For other adverse events, the rituximab entry lists 1 at risk and 1 affected. The alemtuzumab and combination entries each list 0 at risk and 0 affected. These figures are counts as recorded; the registry does not provide event descriptions for the affected participant in these entries, a comparative analysis, or an explanation of the zero at-risk entries for the other groups. In particular, a group with 0 at risk does not provide an estimate of that group’s adverse-event frequency.

As a general statistical point, safety comparisons depend on clear definitions of events, observation time, and denominators. The posted entries do not report those details sufficiently to establish a comparative risk or to determine whether the groups had different safety profiles. The counts should be read descriptively and in the context of the study’s limited enrollment and unavailable primary analysis, not as a basis for concluding that a regimen is safer or more harmful.

12. What the Result Does, and Does Not, Mean

The result recorded for the primary endpoint is not a treatment effect. The registry says no analysis was available because the participant was ineligible for evaluation, and it gives no molecular-remission count at 52 weeks. Therefore, the posted results do not show whether rituximab, alemtuzumab, or their combination differed in MRD flow cytometry-negative status.

This absence of an estimate should not be confused with evidence of no effect. A study can fail to produce an analyzable result without showing that treatments are alike. Equivalence would require a suitable design and an analysis with uncertainty narrow enough to rule out differences of interest; neither is reported. Nor does the lack of a reported result establish that any treatment was effective or ineffective.

The study was terminated due to slow accrual, and enrollment is listed as 1. The record thus documents a trial that did not yield a reported primary comparison. The secondary outcomes of progression-free survival and 52 Week Toxicity Rate are named, but their results are not provided. The posted data cannot support conclusions about those outcomes either.

The safety entries describe few participants at risk in the listed groups and do not include serious adverse event terms. Those entries are not a comprehensive comparative safety analysis. The absence of a serious adverse event term in the registry listing should not be read as proof that no serious events occurred beyond what the record reports, and the group entries with 0 at risk cannot characterize safety for those treatments.

In general, randomized trials can be designed to compare outcomes between assigned groups, but reliable interpretation requires adequate outcome ascertainment and transparent reporting of the analysis. This registry record describes the intended comparison and endpoint definition, yet does not present the data needed to estimate an effect or its precision. Its statistical meaning is therefore mainly about the limits of the evidence available in the record: the treatment question remains unanswered by the posted results.

13. Why This Trial Matters Statistically

This trial is statistically instructive because its design labels and outcome definitions do not guarantee an interpretable treatment comparison. It is registered as randomized and parallel-group, with a defined MRD-based primary endpoint and named secondary outcomes. Yet the record reports enrollment of 1, termination due to slow accrual, and no evaluable primary analysis. The gap between a planned comparison and an analyzable result is central to interpreting clinical-trial evidence.

The record also illustrates why outcome definitions and outcome results must be distinguished. The primary endpoint has a specific definition tied to MRD flow cytometry sensitivity and a stated assessment time of 52 weeks. That clarity is useful for understanding what would have been measured, but it does not reveal how many participants met the endpoint. Without an observed count, an effect estimate, or its uncertainty, statistical comparison is not possible.

It also shows why sparse safety counts need context. The registry lists at-risk and affected counts, but groups with 0 at risk cannot provide a meaningful comparison of adverse-event frequency. Counts alone do not establish comparative safety, particularly when the registry does not report event terms or a detailed analysis.

Finally, the record separates planning assumptions from trial findings. Sample-size illustrations based on specified assumptions are hypothetical planning quantities; they do not demonstrate observed power or recover missing outcome data. For clinical researchers, the general lesson is to read a registry’s design, accrual, analysis status, endpoint definition, and posted results together. When the analysis is unavailable, the most accurate interpretation is a clear account of what was intended and what the record cannot establish.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation is the absence of an evaluable primary outcome analysis. The registry states that the participant was ineligible for evaluation and that the study was terminated due to slow accrual. It reports enrollment of 1, but does not explain the participant’s ineligibility or provide a molecular-remission count. The reason for ineligibility beyond the registry’s statement is not reported in the registry record.

Because no primary comparison is reported, there is no treatment-effect estimate or measure of its precision. The record also does not report baseline characteristics, participant flow, the number screened or excluded, or follow-up details. These omissions prevent assessment of group comparability, outcome ascertainment, and how representative the enrolled participant was of the intended population.

Important design and analysis details are not reported in the registry record, including treatment schedules, allocation concealment, the statistical analysis plan, the trial’s sample-size justification, interim analyses, analysis-population definitions, and missing-data procedures. The registry names secondary outcomes but does not report their analyses. Consequently, neither effectiveness-related outcomes nor comparative safety can be evaluated from the posted results.

The adverse-event entries have limited denominators: the record lists at-risk counts of 1 for rituximab and 0 for the other groups. It does not give serious adverse event terms, and deaths are not reported in the registry record. This limits interpretation of the entries and does not allow a balanced safety comparison across treatment groups.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Alemtuzumab + Rituximab Consolidation in CLL — NCT00771602.
• Registry record last updated 2015-06-23; status last verified 2015-05.
• Results first posted 2011-04-29.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry describes NCT00771602, titled “Alemtuzumab + Rituximab Consolidation in CLL,” as a randomized, parallel-group, unmasked PHASE2 trial sponsored by M.D. Anderson Cancer Center. It studied rituximab alone, alemtuzumab alone, and the combination as consolidation therapy for CLL with residual disease after prior chemo(immuno)therapy.

The primary endpoint was the number of patients with molecular remissions at 52 weeks, defined by MRD flow cytometry-negative status below the assay’s sensitivity limits. Progression-free survival and 52 Week Toxicity Rate are listed as secondary outcomes. Enrollment is listed as 1; the record says the study was terminated due to slow accrual and that no primary analysis was available because the participant was ineligible for evaluation.

The posted results do not provide an evaluable primary comparison, secondary-outcome analyses, or a comparative safety analysis. The registry record therefore documents the trial’s intended question and limited posted outcome information, but does not establish how the treatment groups compared.